259 related articles for article (PubMed ID: 32925722)
1. Prognostic value of long non-coding RNAs in triple negative breast cancer: A PRISMA-compliant meta-analysis.
Zhang S; Ma F; Xie X; Shen Y
Medicine (Baltimore); 2020 Sep; 99(37):e21861. PubMed ID: 32925722
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Differentially Expressed LncRNAs in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.
Tuluhong D; Dunzhu W; Wang J; Chen T; Li H; Li Q; Wang S
Crit Rev Eukaryot Gene Expr; 2020; 30(5):447-456. PubMed ID: 33389881
[TBL] [Abstract][Full Text] [Related]
3. A ten N6-methyladenosine-related long non-coding RNAs signature predicts prognosis of triple-negative breast cancer.
Wu J; Cai Y; Zhao G; Li M
J Clin Lab Anal; 2021 Jun; 35(6):e23779. PubMed ID: 33934391
[TBL] [Abstract][Full Text] [Related]
4. HIF1A-AS2 predicts poor prognosis and regulates cell migration and invasion in triple-negative breast cancer.
Wang Y; Zhang G; Han J
J Cell Biochem; 2019 Jun; 120(6):10513-10518. PubMed ID: 30635931
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of novel three-long noncoding RNA signatures as a diagnostic and prognostic biomarkers of human triple-negative breast cancer.
Fan CN; Ma L; Liu N
J Cell Biochem; 2019 Mar; 120(3):3185-3196. PubMed ID: 30203490
[TBL] [Abstract][Full Text] [Related]
6. LncRNA LUCAT1 facilitates tumorigenesis and metastasis of triple-negative breast cancer through modulating miR-5702.
Mou E; Wang H
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31399501
[TBL] [Abstract][Full Text] [Related]
7. Four-lncRNA immune prognostic signature for triple-negative breast cancer Running title: Immune lncRNAs predict prognosis of TNBC.
Li YX; Wang SM; Li CQ
Math Biosci Eng; 2021 May; 18(4):3939-3956. PubMed ID: 34198419
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Analysis of Differentially Expressed Profiles of lncRNAs/mRNAs and miRNAs with Associated ceRNA Networks in Triple-Negative Breast Cancer.
Yang R; Xing L; Wang M; Chi H; Zhang L; Chen J
Cell Physiol Biochem; 2018; 50(2):473-488. PubMed ID: 30308479
[TBL] [Abstract][Full Text] [Related]
9. A three-long noncoding RNA signature as a diagnostic biomarker for differentiating between triple-negative and non-triple-negative breast cancers.
Liu M; Xing LQ; Liu YJ
Medicine (Baltimore); 2017 Mar; 96(9):e6222. PubMed ID: 28248879
[TBL] [Abstract][Full Text] [Related]
10. LncRNAs as new biomarkers to differentiate triple negative breast cancer from non-triple negative breast cancer.
Lv M; Xu P; Wu Y; Huang L; Li W; Lv S; Wu X; Zeng X; Shen R; Jia X; Yin Y; Gu Y; Yuan H; Xie H; Fu Z
Oncotarget; 2016 Mar; 7(11):13047-59. PubMed ID: 26910840
[TBL] [Abstract][Full Text] [Related]
11. The long non-coding RNA landscape in triple-negative breast cancer.
Zhang W; Guan X; Tang J
Cell Prolif; 2021 Feb; 54(2):e12966. PubMed ID: 33314471
[TBL] [Abstract][Full Text] [Related]
12. LncRNA TCONS_l2_00002973 correlates with less advanced tumor stage and favorable survival, and also inhibits cancer cells proliferation while enhancing apoptosis in triple-negative breast cancer.
Yan J; Wang R; Wu Z
J BUON; 2019; 24(2):535-542. PubMed ID: 31128002
[TBL] [Abstract][Full Text] [Related]
13. Roles of long noncoding RNA in triple-negative breast cancer.
Das PK; Siddika A; Rashel KM; Auwal A; Soha K; Rahman MA; Pillai S; Islam F
Cancer Med; 2023 Oct; 12(20):20365-20379. PubMed ID: 37795578
[TBL] [Abstract][Full Text] [Related]
14. TUG1, SPRY4-IT1, and HULC as valuable prognostic biomarkers of survival in cancer: A PRISMA-compliant meta-analysis.
Zhong Y; Chen Z; Guo S; Liao X; Xie H; Zheng Y; Cai B; Huang P; Liu Y; Zhou Q; Liu Y; Huang W
Medicine (Baltimore); 2017 Nov; 96(46):e8583. PubMed ID: 29145271
[TBL] [Abstract][Full Text] [Related]
15. Advances in Pathophysiology of Triple-Negative Breast Cancer: The Potential of lncRNAs for Clinical Diagnosis, Treatment, and Prognostic Monitoring.
Zhou Y; Yue Y; Fan S; Jia Q; Ding X
Mol Biotechnol; 2021 Dec; 63(12):1093-1102. PubMed ID: 34245439
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of serum exosomal SUMO1P3 predicts unfavorable prognosis in triple negative breast cancer.
Na-Er A; Xu YY; Liu YH; Gan YJ
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):154-160. PubMed ID: 33506903
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNAs in triple-negative breast cancer: A new frontier in the regulation of tumorigenesis.
Thakur KK; Kumar A; Banik K; Verma E; Khatoon E; Harsha C; Sethi G; Gupta SC; Kunnumakkara AB
J Cell Physiol; 2021 Dec; 236(12):7938-7965. PubMed ID: 34105151
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNAs (lncRNAs) in triple negative breast cancer.
Wang Q; Gao S; Li H; Lv M; Lu C
J Cell Physiol; 2017 Dec; 232(12):3226-3233. PubMed ID: 28138992
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
[TBL] [Abstract][Full Text] [Related]
20. Long noncoding RNA GAS5 suppresses triple negative breast cancer progression through inhibition of proliferation and invasion by competitively binding miR-196a-5p.
Li S; Zhou J; Wang Z; Wang P; Gao X; Wang Y
Biomed Pharmacother; 2018 Aug; 104():451-457. PubMed ID: 29793177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
